Innoviva (INVA) Current Assets (2010 - 2026)
Innoviva's (INVA) quarterly Current Assets came in at $772.6 million in Q1 2026, up 32.75% YoY from $582.0 million in Q1 2025, and up 6.2% on a QoQ basis from $727.5 million in Q4 2025.
Analysis
Innoviva (INVA) Current Assets (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Current Assets data on file, last reported at $772.6 million in Q1 2026.
- Quarterly Current Assets rose 32.75% year-over-year to $772.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $772.6 million (up 32.75% YoY) and the FY2025 annual result came in at $727.5 million, up 31.25% from the prior year.
- Current Assets advanced to $772.6 million in Q1 2026, from $727.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $772.6 million in Q1 2026 to a low of $16.9 million in Q3 2025.
- A 5-year average of $364.3 million and a median of $344.2 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets soared 170.02% — and 2024, when it plunged 38.8%.
- Tracing INVA's Current Assets over 5 years: stood at $443.5 million in 2022, then retreated by 22.39% to $344.2 million in 2023, then soared by 61.03% to $554.3 million in 2024, then surged by 31.25% to $727.5 million in 2025, then rose by 6.2% to $772.6 million in 2026.
- The last three Current Assets figures came in at $772.6 million (Q1 2026), $727.5 million (Q4 2025), and $16.9 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | 753.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 753.37 Mn |
| Mar 31, 2026 | 772.62 Mn |
| Dec 31, 2025 | 727.52 Mn |
| Sep 30, 2025 | 684.57 Mn |
| Jun 30, 2025 | 651.78 Mn |
| Mar 31, 2025 | 582.02 Mn |
| Dec 31, 2024 | 554.31 Mn |
| Sep 30, 2024 | 400.62 Mn |
| Jun 30, 2024 | 358.28 Mn |
| Mar 31, 2024 | 311.34 Mn |
| Dec 31, 2023 | 344.22 Mn |
| Sep 30, 2023 | 305.00 Mn |
| Jun 30, 2023 | 323.54 Mn |
| Mar 31, 2023 | 296.45 Mn |
| Dec 31, 2022 | 443.51 Mn |
| Sep 30, 2022 | 454.59 Mn |
| Jun 30, 2022 | 400.33 Mn |
| Mar 31, 2022 | 317.82 Mn |
| Dec 31, 2021 | 313.67 Mn |
| Sep 30, 2021 | 236.93 Mn |